L53 Stock Overview
Operates as a private healthcare company in Southern Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Life Healthcare Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R0.63 |
| 52 Week High | R0.94 |
| 52 Week Low | R0.61 |
| Beta | 0.28 |
| 11 Month Change | 0% |
| 3 Month Change | -0.79% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -55.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| L53 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -0.02% |
| 1Y | n/a | 17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how L53 performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how L53 performed against the German Market.
Price Volatility
| L53 volatility | |
|---|---|
| L53 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: L53's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine L53's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | n/a | Peter Wharton-Hood | www.lifehealthcare.co.za |
Life Healthcare Group Holdings Limited, together with its subsidiaries, operates as a private healthcare company in Southern Africa. It also operates as a research and development pharmaceutical company in the United Kingdom, Europe, the United States, and internationally. The company operates acute hospitals.
Life Healthcare Group Holdings Limited Fundamentals Summary
| L53 fundamental statistics | |
|---|---|
| Market cap | €1.27b |
| Earnings (TTM) | €73.48m |
| Revenue (TTM) | €1.24b |
17.3x
P/E Ratio1.0x
P/S RatioIs L53 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L53 income statement (TTM) | |
|---|---|
| Revenue | R23.76b |
| Cost of Revenue | R17.13b |
| Gross Profit | R6.63b |
| Other Expenses | R5.22b |
| Earnings | R1.41b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 20, 2024
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 27.89% |
| Net Profit Margin | 5.93% |
| Debt/Equity Ratio | 33.1% |
How did L53 perform over the long term?
See historical performance and comparison